Healthcare Attorney Matt Fisher has recently described the “Cost Conundrum of Value-Based Care.” He provides a sober reality check for public and private healthcare sectors as well as healthcare investors. Question: Could cost-benefit analysis better achieve the same goal as value-based payment by attacking the cost problem more directly head on? Value-Based Payment Bandwagon As Attorney … Continue reading Value-Based Care Conundrum for Reforming U.S. Healthcare – A Response
British health economist James Buchanan D.Phil. is skeptical that Geisinger Health System’s (Pa.) genomics project will prove to be cost-effective. But what about the cost-effectiveness of the whole U.S. health system? As a physician and resident of the southern reaches of Geisinger Health System’s catchment area in central Pennsylvania, I was intrigued by Dr. Buchanan’s … Continue reading Cost-Effectiveness: From Genes to Healthcare System Reform
Economist Peter Orszag, who blogs regularly on the economics of healthcare, recently highlighted a survey of healthcare CEOs conducted by his firm Lazard. The survey showed that these CEOs see that “Healthcare is reforming, just not in Washington.” Business (small and large) is rightly fed up with Washington’s petty partisan tinkering with the healthcare system. … Continue reading Response to Peter Orszag: Efficiency Is Not Enough!
The Trump-GOP tax plan will add to the national debt by $1 trillion (Joint Committee on Taxation) or $1.4 trillion (Congressional Budget Office). Under the pay-as-you-go (PAYGO) law, Congress will need to make a choice to cut Medicare or to allow the increase of the national debt. The PAYGO law says that the revenue shortfall … Continue reading Will New Trump-GOP Tax Plan Trigger PAYGO Cuts to Medicare?
Executive Summary Some experts say that cost-benefit analysis is the way to restrain soaring healthcare costs and reform the system. How exactly would cost-benefit analysis work? This blog argues: Forget the caviar. But keep costworthy care on the menu. To explain what this means, let’s look at the case of Repatha (evolocumab), the new cholesterol-lowering drug, … Continue reading FAQ: How Would Cost-Benefit Analysis Be Used to Restrain Healthcare Costs? – The Case of an Expensive New Cholesterol Drug